TOP TIERMARKET NEWSWIRE
News & sentiment

UROGEN PHARMA LTD (URGN) — News & AI sentiment

UROGEN PHARMA LTD (URGN) news roundup. 1 story in the last 24 hours, 1 in the past week, 9 over 30 days. Average 24-hour sentiment is 50/100 — neutral (50 is neutral). Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 4 sales totalling $3.0M — net selling of $3.0M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
1
avg sentiment 50/100
7d stories
1
avg sentiment 50/100
30d stories
9
avg sentiment 56.8/100
Insider net (90d)
$3.0M
0 buys · 4 sells
Congress (90d)
0
0 buys · 0 sells

URGN news in the last 24 hours, 7 days, 30 days and 90 days

How much URGN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowURGN storiesAvg AI sentimentRead
Last 24 hours150/100URGN headlines →
Last 7 days150/100URGN headlines →
Last 30 days956.8/100URGN headlines →
Last 90 days3657.4/100URGN headlines →

Latest stories on URGN

15h ago
Oct 20
UroGen gets FDA review for new bladder cancer therapy
Seeking Alpha63 · neutralproduct/pr
Oct 19
Oct 19
Oct 19
Oct 19
Oct 14
UroGen Pharma: An Emerging GARP Stock
Seeking Alpha63 · neutralanalyst
Oct 13
UroGen Pharma falls -12.8%
The Fly32 · bearishgeneral
Oct 8
Sep 23
Sep 21
Jefferies reiterates UroGen Pharma stock rating on rival drug data
Investing.com Analyst Ratings52 · neutralanalyst
Sep 10
Urogen Pharma: Upside After Bladder Cancer Launch
Seeking Alpha67 · bullishproduct/pr
Sep 9
Sep 4
Sep 4
Sep 2
Sep 2
Aug 21
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing
Investing.com Analyst Ratings56 · neutralanalyst
Aug 20
Aug 20
Aug 20
Aug 20
UroGen Pharma Ltd. (URGN) files 8-K
SEC 8-K50 · neutralgeneral
Aug 20
Aug 20
UroGen Pharma submits UGN-103 NDA to FDA
The Fly63 · neutralgeneral
Aug 17
Open URGN in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →